sPLA2 inhibitor 1
sPLA2 inhibitor 1 structure
|
Common Name | sPLA2 inhibitor 1 | ||
|---|---|---|---|---|
| CAS Number | 393569-31-8 | Molecular Weight | 487.63 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 720.9±60.0 °C at 760 mmHg | |
| Molecular Formula | C31H37NO4 | Melting Point | N/A | |
| MSDS | USA | Flash Point | 389.8±32.9 °C | |
Use of sPLA2 inhibitor 1sPLA2 inhibitor 1, a D-tyrosine derivative, is an orally active, potent secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 29 nM for human nonpancreatic secretory PLA2 isoform IIa (hnpsPLA2-IIa). sPLA2 inhibitor 1 has anti-inflammatory activity[1]. |
| Name | KH064 |
|---|---|
| Synonym | More Synonyms |
| Description | sPLA2 inhibitor 1, a D-tyrosine derivative, is an orally active, potent secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 29 nM for human nonpancreatic secretory PLA2 isoform IIa (hnpsPLA2-IIa). sPLA2 inhibitor 1 has anti-inflammatory activity[1]. |
|---|---|
| Related Catalog | |
| Target |
sPLA2:29 nM (IC50) |
| In Vivo | sPLA2 inhibitor 1 (compound 2b; oral; 5 mg/kg/day; on Days 10-13 after inoculation with arthritogen) shows substantial inhibition of the oedema. Drug-treated rats shows mild capsular oedema and minimal infiltration of macrophages into the red pulp[1]. |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 720.9±60.0 °C at 760 mmHg |
| Molecular Formula | C31H37NO4 |
| Molecular Weight | 487.63 |
| Flash Point | 389.8±32.9 °C |
| Exact Mass | 487.272247 |
| LogP | 6.16 |
| Vapour Pressure | 0.0±2.4 mmHg at 25°C |
| Index of Refraction | 1.573 |
| Storage condition | 2-8°C |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Safety Phrases | 22-24/25 |
| RIDADR | NONH for all modes of transport |
|
Inhibitors of secretory phospholipase A2 group IIA.
Curr. Med. Chem. 12(25) , 3011-26, (2005) Phospholipases A2 cleave membrane phospholipids to release arachidonic acid, the precursor to a large family of pro-inflammatory eicosanoids including prostaglandins and leukotrienes that have been pr... |
|
|
Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats.
J. Immunol. 176(11) , 7000-7, (2006) The development of fibrosis in the chronically hypertensive heart is associated with infiltration of inflammatory cells and cardiac hypertrophy. In this study, an inhibitor of the proinflammatory enzy... |
|
|
Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells.
J. Thorac. Cardiovasc. Surg. 144(6) , 1479-85, (2012) There are currently no targeted therapies against lung tumors with oncogenic K-ras mutations that are found in 25% to -40% of lung cancers and are characterized by their resistance to epidermal growth... |
| KH064 |
| Benzenepentanoic acid, γ-[(1-oxo-7-phenylheptyl)amino]-4-(phenylmethoxy)-, (γS)- |
| MFCD06411576 |
| sPLA2 inhibitor |
| (4S)-5-[4-(Benzyloxy)phenyl]-4-[(7-phenylheptanoyl)amino]pentanoic acid |
| 5-(4-Benzyloxyphenyl)-4S-(7-phenylheptanoylamino)pentanoic acid |